EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Uncovering the transcriptomic basis of endoxifen resistance in ER+ breast cancer cells: Insights from bioinformatics analysis

H Lawrence Remmel, Sandra S Hammer, John R Hawse, Anastasia Shneyderman, Alexander Veviorskiy, Khadija M Alawi, Mikhail Korzinkin, Alex Zhavoronkov, Steven C Quay

Cancer Treatment and Research Communications · 2025

DOI: 10.1016/j.ctarc.2025.101044 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Treatment and Research Communications, 2025. Verfasst von H Lawrence Remmel und 8 weiteren Autor:innen. Beteiligte Einrichtung: Atossa Therapeutics Inc., 10202 5th Ave NE Suite 200 Seattle, WA 98125, United States; Department of Pathology, University Medical Center Utrecht, Ut…. Hauptthemen laut MEDLINE: Tamoxifen, Breast Neoplasms, Drug Resistance, Neoplasm, Transcriptome. Die Arbeit nennt 107 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Estrogen receptor alpha-positive (ER+) breast cancer remains a major clinical challenge due to the development of de novo and acquired resistance to endocrine therapy. (Z)-endoxifen (hereafter endoxifen), the most abundant active tamoxifen metabolite, has emerged as a promising drug candidate due to its superior anti-estrogenic activity and favorable side effect profile. This study aimed to elucidate the gene signature(s) associated with endoxifen resistance by employing gene expression analysis, expression signature generation, pathway enrichment analysis, and correlation analysis, using PandaOmics, a commercially available target-discovery platform. Changes in gene expression and pathways in resistant cells were compared to those seen in sensitive cells upon endoxifen treatment. Resistant cells were characterized by stronger inhibition of the estrogen response, partial retention of endoxifen's antiproliferative effects, acquired activation of proinflammatory pathways and epithelial-mesenchymal transition (EMT), activation of the mTOR pathway (contrasting with its inhibition in sensitive cells), and elevated levels of PKCβ. These resistance-specific changes may potentially drive an endoxifen resistance phenotype and, therefore, proteins involved in these pathways may be proposed as potential therapeutic targets for overcoming endoxifen resistance in breast cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TamoxifenBreast NeoplasmsDrug Resistance, NeoplasmTranscriptomeHumansFemaleComputational BiologyGene Expression Regulation, NeoplasticCell Line, TumorAntineoplastic Agents, HormonalGene Expression ProfilingEstrogen Receptor alpha

Stichwörter der Autor:innen

(Z)-endoxifenBreast cancerER+EstrogenPKCb1SERMTherapy resistance

Substanzen

Tamoxifen4-hydroxy-N-desmethyltamoxifenAntineoplastic Agents, HormonalEstrogen Receptor alpha

Autor:innen und Institutionen

  • Atossa Therapeutics Inc., 10202 5th Ave NE Suite 200 Seattle, WA 98125, United States; Department of Pathology, University Medical Center Utrecht, Utrecht, the Netherlands.
  • Atossa Therapeutics Inc., 10202 5th Ave NE Suite 200 Seattle, WA 98125, United States. Electronic address: sandra.hammer@atossainc.com.
  • Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, Minnesota, United States.
  • Insilico Medicine Hong Kong Ltd., Hong Kong Science and Technology Park, Hong Kong, Hong Kong SAR, China.
  • Insilico Medicine AI Limited, Abu Dhabi, UAE.
  • Insilico Medicine Hong Kong Ltd., Hong Kong Science and Technology Park, Hong Kong, Hong Kong SAR, China; Insilico Medicine AI Limited, Abu Dhabi, UAE; Insilico Medicine Canada Inc., 3710-1250 René-Lévesque Blvd. W, Mon…

Zitieren

APA

Remmel, H. L., Hammer, S. S., Hawse, J. R., Shneyderman, A., Veviorskiy, A., Alawi, K. M., Korzinkin, M., Zhavoronkov, A., & Quay, S. C. (2025). Uncovering the transcriptomic basis of endoxifen resistance in ER+ breast cancer cells: Insights from bioinformatics analysis. Cancer Treatment and Research Communications. https://doi.org/10.1016/j.ctarc.2025.101044

Vancouver

Remmel HL, Hammer SS, Hawse JR, Shneyderman A, Veviorskiy A, Alawi KM, et al. Uncovering the transcriptomic basis of endoxifen resistance in ER+ breast cancer cells: Insights from bioinformatics analysis. Cancer Treatment and Research Communications. 2025. doi:10.1016/j.ctarc.2025.101044

BibTeX
@article{Remmel2025,
  author = {Remmel, H Lawrence and Hammer, Sandra S and Hawse, John R and Shneyderman, Anastasia and Veviorskiy, Alexander and Alawi, Khadija M and Korzinkin, Mikhail and Zhavoronkov, Alex and Quay, Steven C},
  title = {Uncovering the transcriptomic basis of endoxifen resistance in ER+ breast cancer cells: Insights from bioinformatics analysis},
  journal = {Cancer Treatment and Research Communications},
  year = {2025},
  doi = {10.1016/j.ctarc.2025.101044}
}
Kostenlos starten →